[go: up one dir, main page]

PL1633364T3 - Sposób wytwarzania zasady sildenafilu i cytrynianu sildenafilu - Google Patents

Sposób wytwarzania zasady sildenafilu i cytrynianu sildenafilu

Info

Publication number
PL1633364T3
PL1633364T3 PL05705020T PL05705020T PL1633364T3 PL 1633364 T3 PL1633364 T3 PL 1633364T3 PL 05705020 T PL05705020 T PL 05705020T PL 05705020 T PL05705020 T PL 05705020T PL 1633364 T3 PL1633364 T3 PL 1633364T3
Authority
PL
Poland
Prior art keywords
sildenafil
processes
production
citrate salt
sildenafil base
Prior art date
Application number
PL05705020T
Other languages
English (en)
Inventor
Viviana Braude
Judith Aronhime
Shalom Shabat
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of PL1633364T3 publication Critical patent/PL1633364T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL05705020T 2004-01-05 2005-01-05 Sposób wytwarzania zasady sildenafilu i cytrynianu sildenafilu PL1633364T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53452704P 2004-01-05 2004-01-05
US54723204P 2004-02-23 2004-02-23
US54926804P 2004-03-01 2004-03-01
EP05705020A EP1633364B1 (en) 2004-01-05 2005-01-05 Processes for the production of sildenafil base and citrate salt
PCT/US2005/000207 WO2005067936A2 (en) 2004-01-05 2005-01-05 Methods for the production of sildenafil base and citrate salt

Publications (1)

Publication Number Publication Date
PL1633364T3 true PL1633364T3 (pl) 2008-07-31

Family

ID=34799609

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05705020T PL1633364T3 (pl) 2004-01-05 2005-01-05 Sposób wytwarzania zasady sildenafilu i cytrynianu sildenafilu

Country Status (11)

Country Link
US (1) US7618976B2 (pl)
EP (1) EP1633364B1 (pl)
JP (1) JP2007517803A (pl)
AT (1) ATE387203T1 (pl)
CA (1) CA2552003A1 (pl)
DE (1) DE602005004966T2 (pl)
ES (1) ES2300979T3 (pl)
IL (1) IL175635A0 (pl)
PL (1) PL1633364T3 (pl)
PT (1) PT1633364E (pl)
WO (1) WO2005067936A2 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009125415A1 (en) * 2008-04-07 2009-10-15 Hetero Research Foundation Amorphous form of sildenafil citrate
WO2010025266A1 (en) * 2008-08-27 2010-03-04 University Of Iowa Research Foundation Inhibitors of phosphodiesterase type 5a for treating or preventing muscle disease or the symptoms thereof in a patient
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
NO2723977T3 (pl) 2014-03-19 2018-03-10
CN104370915A (zh) * 2014-11-06 2015-02-25 成都医路康医学技术服务有限公司 枸橼酸西地那非的制备方法
EP3331888A4 (en) * 2015-08-03 2019-03-20 Synergistic Therapeutics, LLC THERAPEUTIC GEL FOR SEXUAL DYSFUNCTION
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN111116591A (zh) * 2018-10-30 2020-05-08 天津科伦药物研究有限公司 一种制备枸橼酸西地那非的方法
US12383559B2 (en) * 2023-03-09 2025-08-12 YourLifeRx, Inc. Rehydration composition and method of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4302446A (en) 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
SE457326B (sv) 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5271944A (en) 1991-04-05 1993-12-21 Biofor, Ltd. Pharmacologically enhanced formulations
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
EA002057B1 (ru) * 1997-04-25 2001-12-24 Пфайзер Инк. ПИРАЗОЛОПИРИМИДИНОНЫ, КОТОРЫЕ ИНГИБИРУЮТ ЦИКЛИЧЕСКИЙ ГУАНОЗИН-3',5'-МОНОФОСФАТ-ФОСФОДИЭСТЕРАЗУ ТИПА 5 (cGMP PDE5), ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОГО РАССТРОЙСТВА
CN1094492C (zh) * 1999-06-21 2002-11-20 杭州神鹰医药化工有限公司 西地那非的制备方法
WO2001087888A1 (en) * 2000-05-17 2001-11-22 Sk Chemicals Co., Ltd. Pyrazolopyrimidinone derivatives, process for their preparation and their use
US6730786B2 (en) 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
KR100393160B1 (ko) 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
WO2004072079A1 (en) 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
ES2300979T3 (es) 2008-06-16
JP2007517803A (ja) 2007-07-05
DE602005004966T2 (de) 2009-03-12
US7618976B2 (en) 2009-11-17
DE602005004966D1 (de) 2008-04-10
US20050182066A1 (en) 2005-08-18
WO2005067936A2 (en) 2005-07-28
ATE387203T1 (de) 2008-03-15
EP1633364B1 (en) 2008-02-27
EP1633364A2 (en) 2006-03-15
WO2005067936A3 (en) 2005-12-08
IL175635A0 (en) 2006-09-05
CA2552003A1 (en) 2005-07-28
PT1633364E (pt) 2008-05-29

Similar Documents

Publication Publication Date Title
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
GEP20104895B (en) Preparation of pregabalin and related compounds
IL185031A0 (en) Method for the preparation of pregabalin and salts thereof
EP2325186A3 (en) Fused Bicyclic mTor Inhibitors
MX2010006107A (es) Derivados de espiroindolinona.
TW200613243A (en) Novel compounds
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
MX2010003495A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas.
WO2008062282A3 (en) An improved process for the synthesis of solifenacin
PT1633364E (pt) Métodos para a produção de sildenafil base e sal citrato de sildenafil
WO2007059008A3 (en) N-substituted indenoisoquinolines and syntheses thereof
TW200615272A (en) Crystalline mycophenolate sodium
MX2007006743A (es) Ligandos del receptor de acetilcolina nicotinica.
WO2009022327A3 (en) Novel process for preparing highly pure levocetirizine and salts thereof
TW200617006A (en) New process for the manufacture of tiotropium salts
TW200609200A (en) Preparation of levalbuterol hydrochloride
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
EP1779852A3 (en) Processes for the production of sildenafil base and citrate salt
MX2009005804A (es) Composicion farmaceutica de memantina.
ITMO20050001A1 (it) Procedimento per la produzione di oggetti decorativi puzzle.
TW200638932A (en) CCI-779 polymorph and use thereof
NZ595482A (en) Method of treating osteoporosis
PL1718651T3 (pl) Pochodne 7H-pirolopirymidyny
GEP20084503B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them